ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Audit on the Managment in Assiut University Children Hospital

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03281863
Recruitment Status : Not yet recruiting
First Posted : September 13, 2017
Last Update Posted : September 15, 2017
Sponsor:
Information provided by (Responsible Party):
Patricia reda hanna, Assiut University

Brief Summary:
clinical audit on the Managment of rheumatic fever in assiut university children hospital.

Condition or disease Intervention/treatment
Rheumatic Fever Diagnostic Test: C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate

Detailed Description:

Acute rheumatic fever,an auto immune response to Group A streptococcus infection of the upper respiratory tract,may result in carditis.when the inflammation leads to permenant damage of the valves the individual has rheumatic heart disease.

Recurrences of rheumatic fever are likely in the absence of preventive measures and may cause further cardiac valve and muscle damage,leading to heart failure,stroke and premature death.bacterial endocarditis is also a complication.


Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Audit on the Managment of Rheumatic Fever in Assiut University Children Hospital
Estimated Study Start Date : October 1, 2017
Estimated Primary Completion Date : September 29, 2018
Estimated Study Completion Date : September 29, 2018

Resource links provided by the National Library of Medicine



Intervention Details:
  • Diagnostic Test: C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate
    Throat culture to detect the causative organism
    Other Name: Throat culture


Primary Outcome Measures :
  1. laboratory investigations (ASOt , ESR . CRP) [ Time Frame: One year from October 2017 to september 2018 ]
    laboratory investigations that measure the inflammation process will be used and the target that the ASOt not increase 1/400


Secondary Outcome Measures :
  1. clinical measures [ Time Frame: One year from October 2017 to september 2018 ]
    improvement of arthritis if found



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Clinical audit on the managment of rheumatic fever in assiut university children hospital
Criteria

Inclusion Criteria:

  • patients with confirmed diagnosis of rheumatic fever based on laboratory investigations.

Exclusion Criteria:


Responsible Party: Patricia reda hanna, Resident doctor, Assiut University
ClinicalTrials.gov Identifier: NCT03281863     History of Changes
Other Study ID Numbers: AssiutU71516
First Posted: September 13, 2017    Key Record Dates
Last Update Posted: September 15, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Fever
Rheumatic Fever
Rheumatic Diseases
Body Temperature Changes
Signs and Symptoms
Musculoskeletal Diseases
Connective Tissue Diseases
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Arthritis
Joint Diseases
Antibodies
Antistreptolysin
Immunologic Factors
Physiological Effects of Drugs